The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
ORAL DRUG THERAPY FOR ERECTILE DYSFUNCTION
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, in the presence of high-fat food, absorption of sildenafil and vardenafil may be delayed; however, the rate and extent of tadalafil absorption are unaffected by highfat food.”
From Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles (2004) · cites this paper as [6]
In the citing paper
“Administration of sildenafil with a high-fat meal reduces the C max by about 29% 6 (Table I) and delays the time to achieve peak plasma concentration, or T max , by about 1 h.6”
From Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles (2004) · cites this paper as [6]
In the citing paper
“Conversely, tadalafil is a weak inhibitor of PDE6 compared with either sildenafil or vardenafil and may account for the rare occurrence of color vision abnormalities (< 0.1%) with tadalafil.6,7”
From Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles (2004) · cites this paper as [6]
In the citing paper
“For example, sildenafil is a relatively potent inhibitor of PDE6 (localized in the rods and cones of the retina), which may explain the color vision disturbances reported in up to 11% of men receiving sildenafil.6”
From Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles (2004) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Self-citation
Research works printed but not linked: 32
- Boolell, 1996, Sildenafil: An orally active type 5 cyclic GMP–specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, Int J Impot Res, 8, 47
- Cheitlin, 1999, Use of sildenafil (Viagra) in patients with cardiovascular disease, J Am Coll Cardiol, 33, 273, 10.1016/S0735-1097(98)00656-1 · DOI · Paper page
- Conti, 1999, Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease, Am J Cardiol, 83, 29C, 10.1016/S0002-9149(99)00045-4 · DOI
- R DeBusk, Y Drory, I Goldstein, et al, Management of sexual dysfunction in patients with cardiovascular diseases: Recommendations of the Princeton Consensus Panel. Am J Cardiol, in press
- Derry, 1998, Efficacy and safety of oral sildenafil in men with erectile dysfunction caused by spinal cord injury, Neurology, 51, 1629, 10.1212/WNL.51.6.1629 · DOI
- Derry, 1997, Sildenafil: A double blind placebo controlled single dose 2-way crossover study in men with erectile dysfunction caused by traumatic spinal cord injury, J Urol, 157, 181
- Duncker, 1995, Nitrovasodilators ITF 296 and isosorbide dinitrate exert anti-ischemic activity by dilating coronary penetrating arteries, J Cardiovasc Pharmacol, 25, 823, 10.1097/00005344-199505000-00020 · DOI
- Fugl-Meyer, 1997, On life satisfaction in male erectile dysfunction, Int J Impot Res, 9, 141, 10.1038/sj.ijir.3900269 · DOI · Paper page
- Herrmann, 2000, Hemodynamic effects of sildenafil in men with severe coronary artery disease, N Engl J Med, 342, 1622, 10.1056/NEJM200006013422201 · DOI · Paper page
- Holmgren, 1998, Sildenafil in the treatment of erectile dysfunction caused by spinal cord injury: A double blind placebo controlled flexible dose 2-way crossover study, Neurology, 50, A127
- Ishibashi, 1997, The nitric oxide donor ITF 1129 augments subendocardial blood flow during exercise-induced myocardial ischemia, J Cardiovasc Pharmacol, 30, 374, 10.1097/00005344-199709000-00016 · DOI
- Jackson, 1999, Effects of sildenafil citrate on human hemodynamics, Am J Cardiol, 83, 13C, 10.1016/S0002-9149(99)00043-0 · DOI · Paper page
- SD Katz, K Balidemaj, S Homma, et al. Acute type 5 phosphodiesterase inhibition with sildenafil enhances endothelium-dependent, flow-mediated vasodilation in patients with chronic heart failure [abstract 500082]. In Programs and Abstracts of the American Heart Association Annual Meeting, Annaheim, CA, 2000. · DOI · Paper page
- Lue, 2000, Drug therapy: Erectile dysfunction, N Engl J Med, 342, 1802, 10.1056/NEJM200006153422407 · DOI · Paper page
- Melis, 1996, Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: Correlation in penile erection and yawning, Eur J Neurosci, 8, 2056, 10.1111/j.1460-9568.1996.tb00725.x · DOI
- Mittleman, 2000, Incidence of myocardial infarction and death in 53 clinical trials of Viagra (sildenafil citrate), J Am Coll Cardiol, 35, 302A
- Morales, 1998, Clinical safety of sildenafil citrate (Viagra) in the treatment of erectile dysfunction, Int J Impot Res, 10, 69, 10.1038/sj.ijir.3900354 · DOI · Paper page
- Muller, 1996, Triggering myocardial infarction by sexual activity, JAMA, 275, 1405, 10.1001/jama.1996.03530420033032 · DOI
- NIH Consensus Development Panel on Impotence, 1993, Impotence, JAMA, 270, 83, 10.1001/jama.1993.03510010089036 · DOI · Paper page
- Padma-Nathan, 1998, A 24-week, fixed-dose study to assess the efficacy and safety of sildenafil (Viagra) in men with erectile dysfunction, J Urol, 159, 238A
- Padma-Nathan, 1998, Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: A double blind, placebo-controlled study of 329 patients, Int J Clin Pract, 52, 1, 10.1111/j.1742-1241.1998.tb08886.x · DOI
- H adma-Nathan, RC Rosen, RW Lewis, et al.Sublingual apomorphine for the treatment of male erectile dysfunction. (in press)
- Price, 1997, Sildenafil, A novel oral therapy for penile erectile dysfunction in patients with diabetes, Diabet Med, 14, A6
- Rendell, 1999, Sildenafil for the treatment of erectile dysfunction in men with diabetes, JAMA, 281, 421, 10.1001/jama.281.5.421 · DOI
- Rosen, 1997, The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction, Urology, 49, 822, 10.1016/S0090-4295(97)00238-0 · DOI · Paper page
- Segraves, 1991, Effect of apomorphine on penile tumescence in men with psychogenic impotence, J Urol, 145, 1174, 10.1016/S0022-5347(17)38565-8 · DOI
- Steers, 1998, Meta-analysis of the efficacy of sildenafil (Viagra) in the treatment of severe erectile dysfunction, J Urol, 159, 238A
- Steif, 2000, The effect of sildenafil on cAMP levels in human cardiac tissue: A possible explanation for cardiovascular side effects, J Am Coll Cardiol, 35
- Wagner, 1998, Analysis of the efficacy of sildenafil (Viagra) in the treatment of male erectile dysfunction in elderly patients, J Urol, 159, 238A
- Webb, 1999, Sildenafil citrate and blood-pressure lowering drugs: Results of drug interaction studies with organic nitrate and a calcium antagonist, Am J Cardiol, 83, 21C, 10.1016/S0002-9149(99)00044-2 · DOI · Paper page
- Zippi, 2000, Role of Viagra after radical prostatectomy, Urology, 55, 241, 10.1016/S0090-4295(99)00441-0 · DOI
- Zusman, 1999, Overall cardiovascular profile of sildenafil citrate, Am J Cardiol, 83, 35C, 10.1016/S0002-9149(99)00046-6 · DOI
Cited by
Dopamine and serotonin: influences on male sexual behavior
Hull, E. M., Muschamp, J. W., & Sato, S. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.08.018 · Cited by 465
PHARMACOLOGY OF PHOSPHODIESTERASE‐5 INHIBITORS
Corbin, J., & Francis, S. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11296.x · Cited by 260
Seftel, A. D. (2004) · Clinical Cardiology · doi:10.1002/clc.4960271305 · Cited by 79
Tadalafil: a novel treatment for erectile dysfunction
GIULIANO, F. (2002) · European Heart Journal Supplements · doi:10.1016/s1520-765x(02)90049-0 · Cited by 21
Self-citation
Metadata
- Authors
- Padma-Nathan, H., & Giuliano, F.
- Venue
- Urologic Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2001-05
- Volume
- 28
- Issue
- 2
- Pages
- 321-334
- ISSN
- 0094-0143
- Cited by
- 77
- References
- 1
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
